These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. RIG-I-Like Receptor-Mediated Recognition of Viral Genomic RNA of Severe Acute Respiratory Syndrome Coronavirus-2 and Viral Escape From the Host Innate Immune Responses. Kouwaki T; Nishimura T; Wang G; Oshiumi H Front Immunol; 2021; 12():700926. PubMed ID: 34249006 [TBL] [Abstract][Full Text] [Related]
9. Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory Distress Syndrome. Hue S; Beldi-Ferchiou A; Bendib I; Surenaud M; Fourati S; Frapard T; Rivoal S; Razazi K; Carteaux G; Delfau-Larue MH; Mekontso-Dessap A; Audureau E; de Prost N Am J Respir Crit Care Med; 2020 Dec; 202(11):1509-1519. PubMed ID: 32866033 [No Abstract] [Full Text] [Related]
10. SARS-CoV-2 and its beta variant of concern infect human conjunctival epithelial cells and induce differential antiviral innate immune response. Singh S; Garcia G; Shah R; Kramerov AA; Wright RE; Spektor TM; Ljubimov AV; Arumugaswami V; Kumar A Ocul Surf; 2022 Jan; 23():184-194. PubMed ID: 34583089 [TBL] [Abstract][Full Text] [Related]
11. Circulating Type I Interferon Levels in the Early Phase of COVID-19 Are Associated With the Development of Respiratory Failure. Nagaoka K; Kawasuji H; Murai Y; Kaneda M; Ueno A; Miyajima Y; Fukui Y; Morinaga Y; Yamamoto Y Front Immunol; 2022; 13():844304. PubMed ID: 35237279 [TBL] [Abstract][Full Text] [Related]
12. Proteomic Signature of Host Response to SARS-CoV-2 Infection in the Nasopharynx. Vanderboom PM; Mun DG; Madugundu AK; Mangalaparthi KK; Saraswat M; Garapati K; Chakraborty R; Ebihara H; Sun J; Pandey A Mol Cell Proteomics; 2021; 20():100134. PubMed ID: 34400346 [TBL] [Abstract][Full Text] [Related]
13. Differentially expressed immune response genes in COVID-19 patients based on disease severity. Li S; Duan X; Li Y; Li M; Gao Y; Li T; Li S; Tan L; Shao T; Jeyarajan AJ; Chen L; Han M; Lin W; Li X Aging (Albany NY); 2021 Mar; 13(7):9265-9276. PubMed ID: 33780352 [TBL] [Abstract][Full Text] [Related]
14. Dexamethasone attenuates interferon-related cytokine hyperresponsiveness in COVID-19 patients. Engel JJ; van der Made CI; Keur N; Setiabudiawan T; Röring RJ; Damoraki G; Dijkstra H; Lemmers H; Ioannou S; Poulakou G; van der Meer JWM; Giamarellos-Bourboulis EJ; Kumar V; van de Veerdonk FL; Netea MG; Ziogas A Front Immunol; 2023; 14():1233318. PubMed ID: 37614228 [TBL] [Abstract][Full Text] [Related]
15. Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy. Eskandarian Boroujeni M; Sekrecka A; Antonczyk A; Hassani S; Sekrecki M; Nowicka H; Lopacinska N; Olya A; Kluzek K; Wesoly J; Bluyssen HAR Front Immunol; 2022; 13():888897. PubMed ID: 35663932 [TBL] [Abstract][Full Text] [Related]
16. Correlations of Myeloperoxidase (MPO), Adenosine deaminase (ADA), C-C motif chemokine 22 (CCL22), Tumour necrosis factor alpha (TNFα) and Interleukin-6 (IL-6) mRNA expression in the nasopharyngeal specimens with the diagnosis and severity of SARS-CoV-2 infections. Chiu KH; Yip CC; Poon RW; Leung KH; Li X; Hung IF; To KK; Cheng VC; Yuen KY Emerg Microbes Infect; 2023 Dec; 12(1):2157338. PubMed ID: 36482706 [TBL] [Abstract][Full Text] [Related]
18. In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age. Lieberman NAP; Peddu V; Xie H; Shrestha L; Huang ML; Mears MC; Cajimat MN; Bente DA; Shi PY; Bovier F; Roychoudhury P; Jerome KR; Moscona A; Porotto M; Greninger AL PLoS Biol; 2020 Sep; 18(9):e3000849. PubMed ID: 32898168 [TBL] [Abstract][Full Text] [Related]
19. Predictive values of immune indicators on respiratory failure in the early phase of COVID-19 due to Delta and precedent variants. Nagaoka K; Kawasuji H; Takegoshi Y; Murai Y; Kaneda M; Kimoto K; Morimoto S; Tani H; Niimi H; Morinaga Y; Yamamoto Y Front Immunol; 2023; 14():1197436. PubMed ID: 37731495 [TBL] [Abstract][Full Text] [Related]
20. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2. Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG mBio; 2020 Sep; 11(5):. PubMed ID: 32913009 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]